福瑞达(600223) - 2024 Q4 - 年度财报

Financial Performance - The net profit attributable to the parent company for 2024 is CNY 243,525,296, with the parent company achieving a net profit of CNY 161,150,457.99[6]. - The company's operating revenue for 2024 was CNY 3,982,577,119.73, a decrease of 13.02% compared to 2023[23]. - Net profit attributable to shareholders for 2024 was CNY 243,525,296.00, down 19.73% from the previous year[23]. - The net profit after deducting non-recurring gains and losses increased by 54.54% to CNY 214,624,949.50 compared to 2023[23]. - The total profit for the year was CNY 346 million, down 16.14% compared to the previous year[68]. - The company’s net assets attributable to shareholders grew by 2.24% to CNY 4.11 billion[68]. - The company reported a significant reduction in short-term borrowings by 69.92%, down to CNY 212,116,144.16, as a result of repaying bank loans[95]. Dividend Distribution - The total cash dividend for the year, including the interim distribution, amounts to CNY 111,822,565.25, representing 45.92% of the net profit attributable to shareholders[7]. - The proposed cash dividend distribution is CNY 0.6 per 10 shares, totaling CNY 60,994,126.50, subject to shareholder approval[6]. - The company announced a cash dividend of CNY 111,822,565.25, which accounts for 45.92% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 243,525,296.00[195]. - The cumulative cash dividend over the last three accounting years is CNY 213,479,442.75, with an average net profit of CNY 197,455,937.04, resulting in a cash dividend ratio of 108.11%[197]. Assets and Liabilities - Total assets at the end of 2024 were CNY 6,000,330,923.23, a decrease of 23.25% from the end of 2023[23]. - The company’s cash and cash equivalents increased by 70.04% to CNY 2,947,718,857.86, primarily due to the receipt of remaining payments from the real estate business divestiture[95]. - Accounts receivable decreased by 38.09% to CNY 42,208,300.08, mainly due to the settlement of notes[95]. - The remaining undistributed profit for the parent company is CNY 478,213,079.30, to be carried forward to future years[6]. Research and Development - The company invested 199 million yuan in R&D in 2024, representing a year-on-year increase of 20.05%[38]. - The number of R&D personnel is 430, accounting for 11.85% of the total workforce[89]. - Total R&D investment amounted to 198.72 million RMB, which is 4.99% of total revenue, with 16.08% of R&D costs capitalized[88]. - The company launched over 140 new cosmetic products and received 64 new patent authorizations, including 42 invention patents[38]. Market Performance - In 2024, the cosmetics segment achieved revenue of 2.475 billion yuan, a year-on-year increase of 2.46%, with a gross margin of 62.57%[35]. - The Yilian brand generated revenue of 963 million yuan, up 12.36% year-on-year, while the Ai'er Doctor brand saw a revenue decline of 3.48% to 1.301 billion yuan[35]. - The pharmaceutical segment reported revenue of 512 million yuan, a decrease of 1.41%, with a gross margin of 52.32%[36]. - The company achieved a sales growth of 37% for its Tongxuan Li Fei capsules, with over 360,000 boxes sold[36]. Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring all shareholders, especially minority shareholders, could exercise their voting rights[154]. - The board of directors convened 9 meetings during the reporting period, maintaining compliance with legal and regulatory requirements[154]. - The company emphasizes the importance of intellectual property protection and the commercialization of research outcomes[52]. - The company’s governance structure includes independent directors and supervisors to ensure compliance and accountability[168]. Strategic Initiatives - The company is focused on technological innovation and high-end transformation in the raw materials sector, driven by the increasing demand for natural and green ingredients[45]. - The company is actively expanding its market presence through strategic partnerships and product innovation, aiming to capture emerging market opportunities in both cosmetics and pharmaceuticals[44]. - The company is implementing a "1234" high-quality innovation development strategy, focusing on enhancing its leading position in hyaluronic acid and optimizing its pharmaceutical and cosmetics segments[135]. - The company is committed to integrating raw material and formulation development, accelerating the registration of pharmaceutical-grade hyaluronic acid domestically and internationally[137]. Environmental and Social Responsibility - The company emphasizes environmental protection and safety management, committing to enhance training and risk control measures[150]. - The company is committed to green development and increasing investment in environmental protection to ensure compliance with emission standards[150]. - The company is closely monitoring policy changes in the cosmetics and pharmaceutical sectors to mitigate potential risks and adapt its strategies accordingly[145]. Human Resources - The total number of employees across the parent company and major subsidiaries is 3,630, with 1,235 in production, 560 in sales, and 1,280 in technical roles[184][185]. - The company has established a talent development mechanism to enhance the quality of its workforce and ensure a steady supply of key personnel[187][188]. - The company has implemented a performance-based salary system, linking compensation to operational performance and market competitiveness[186].